|
KMID : 0438420090160020087
|
|
Korean Journal of Bone Metabolism
2009 Volume.16 No. 2 p.87 ~ p.93
|
|
|
The Use of Osteoporosis Medications in Korea in 2008
|
|
Park Hyoung-Moo
Lee Eun-Sil
Kim Sang-Myung
|
|
|
Abstract
|
|
|
Objective: This study was to evaluate the trend in the use of osteoporosis medications during a year of 2008 and to estimate the trend of treatment for osteoporosis in the future.
Methods: Data from the International Marketing Service (IMS) were used to analyze treatment medication for osteoporosis. Specific pharmacologic and non-pharmacologic treatments analyzed included calcium, hormone (estrogen, estrogen and progestogen combination, and tibolone), oral and intravenous bisphosphonate, raloxifene, calcitonin, vitamin D and others.
Results: The use of calcium have tended to rely on general practice without prescription. Of the cost of osteoporosis medications during a year of 2008, hormone represented about 20% and non-hormone represented about 80%. Bisphosphonates were most commonly used in 2008 and they came to 114 billion and 200 million won (85%) and then vitamin D (11 billion and 200 million won), raloxifene (6 billion and 200 million won), and calcitonin (2 billion won).
Conclusion: The most commonly used osteoporosis medication was bisphosphonates, especially once weekly oral bisphosphonates. Parathyroid hormone, the only bone formation drug, have been limitedly used because it is very expensive and should be given by daily SC injection. As once-monthly oral bisphosphonates and quarterly and yearly IV medications were developed, the increase of use of these medications would be expected.
|
|
|
KEYWORD
|
|
|
Osteoporosis, Medications, Bisphosphonate
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|